Skip to main content
. 2021 Feb 15;12:618279. doi: 10.3389/fpsyt.2021.618279

Figure 1.

Figure 1

(A) Early significant improvements in overall depressive symptomatology as measured by the MADRS and QIDS-SR16. (B) Similar significant improvements in anhedonia as measured by the SHAPS.